n Medical Chronicle - START study and the management of HIV : HIV

Volume 12, Issue 1
  • ISSN : 2617-9385


The Strategic Timing of Antiretroviral Treatment (START) study, a multinational, randomised trial conducted by the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), aimed to determine risks and benefits of the immediate initiation of antiretroviral therapy (ART) in asymptomatic HIV-positive patients who had a CD4+ count of greater than 500 cells/µL as compared with those who were deferred treatment until their CD4+ count was 350 cells/µL or below.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error